Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA

Headlands Technologies LLC purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 18,161 shares of the company's stock, valued at approximately $1,161,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. KBC Group NV acquired a new position in Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $34,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth $41,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $78.63 on Tuesday. The firm has a market cap of $6.13 billion, a PE ratio of 81.06 and a beta of 0.05. The firm has a fifty day moving average of $70.32 and a 200 day moving average of $56.48. Kiniksa Pharmaceuticals International, plc has a one year low of $33.25 and a one year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting the consensus estimate of $0.30. The company had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Weiss Ratings cut Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 12th. JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. The Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Finally, Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $87.38.

Insiders Place Their Bets

In other news, Director G Bradley Cole sold 3,673 shares of the firm's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company's stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 51.98% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source